ClinicalTrials.gg
TerminatedNCT04243837Updated Apr 23, 2024Results posted

LYT-100 in Patients With BCRL

A Phase 2 interventional study of LYT-100 BCRL and Placebo BCRL in Breast Cancer Related Lymphoedema and Lymphoedema, sponsored by PureTech. Terminated at 8 sites in 2 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-23.

Sponsored by PureTech · Phase 2, Interventional, and Treatment

Why this study was terminated
Primary objective/endpoint has been established, will not pursue development of the disease indication further

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 168 studies in Lymphedema with a site in United States — 37 open to participants now, 45 under way, 1 of them phase 3. Lymphedema · United States.

Enrollment
60th of 122
50 · median 50
Started
2020
with 9 others
Phase 2
19 of 168
4 open now
Registered
107th of 168
by date

Among the 168 studies in Lymphedema with a site in United States, this one is the 60th largest by enrollment of the 122 interventional ones that give a count, is one of 10 that started in 2020, is one of 19 in phase 2, and was the 107th registered.

Lymphedema

529 studies on the registry are indexed under Lymphedema; 130 are open to participants now.

Browse Lymphedema studies →

Open to participants now

37 of the 168 studies in Lymphedema with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 85 Lymphedema studies recruiting now, 46 (54%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 168 studies in Lymphedema with a site in United States, or all of them as a file.
02

Study summary

This is a trial of up to 6-months duration for safety, tolerability, clinical efficacy assessments, PK and biomarkers analysis in breast carcinoma patients with secondary lymphoedema

Read the detailed description

This trial will utilize a randomised, double-blinded, placebo controlled design that will assess the safety, tolerability, and secondarily clinical efficacy of LYT-100 over a period of up to 6-months of dosing in breast carcinoma patients with secondary lymphoedema following sentinel lymph node biopsy and/or axillary node dissection, with or without radiation.

03

Conditions studied

  • Breast Cancer Related Lymphoedema
  • Lymphoedema

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Main Inclusion Criteria:

  1. Female or male between 18 and 80 years old (inclusive) at the time of .
  2. At least 6 months since any type of breast cancer surgery (excluding fine needle aspiration [FNA]), at the time of study screening. No intention to have breast reconstructive surgery, nipple reconstruction and/or tattooing during the course of the study.
  3. At least 3 months since completion of all types of treatment for breast cancer, including but not limited to , radiotherapy, chemotherapy and immunotherapy, at the time of study screening.
  4. At least 3 months treatment of stable adjuvant treatment with hormonal or anti- therapy at the time of screening, with no planned changes to this therapy throughout the duration of the study.
  5. Diagnosis of primary breast cancer, and without evidence of recurrence of breast cancer and/or for at least 6 months since breast cancer surgery, as determined at screening and baseline.
  6. Documented evidence of Stage 1 or 2 lymphedema.
  7. Receiving standard of care compression or agreeable to using care compression, or no compression at all ≥ 4 weeks prior to screening and throughout the study.

Main Exclusion Criteria:

  1. Bilateral lymphoedema or history of bilateral axillary lymph node removal (i.e., sentinel lymph node or axillary lymph node dissection), or primary lymphoedema or lymphatic or vascular malformation, determined at screening.
  2. Chronic administration (defined as more than 14 consecutive days) of or other immune-modifying drugs within 3 months prior to study drug administration; are permitted at the discretion of the PI.
  3. Recent history (in the 8 weeks prior to screening) of cellulitis, lymphangitis, dermatitis, necrotizing fasciitis, or current open wounds or sores in the affected extremity.
  4. Stage III lymphoedema, or history of clinically diagnosed secondary lymphoedema greater than 4 years, determined at screening.
  5. Initiated use of compression or manual lymphatic drainage or other lymphoedema therapies at the start of the study within 4 weeks of the screening visit. Rescreening is allowed following a course of stable compression regimen of > 4 weeks.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    LYT-100 in patients with BCRL

    LYT-100 BID for 6 months

    Drug: LYT-100 BCRL

  • Placebo comparator
    Placebo in patients with BCRL

    Placebo BID for 6 months

    Drug: Placebo BCRL

Interventions

  • BCRL patients will receive LYT-100 BID for 6 months

    Also known as: Deupirfenidone

  • DrugPlacebo BCRL

    BCRL patients will receive Placebo BID for 6 months

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Evaluate the safety and tolerability of LYT-100 as measured by TEAEs

    Time frame: 6 months

07

Results

Posted Apr 23, 2024

Participant flow

Participant flow — Overall Study
MilestoneLYT-100 in Patients With BCRLPlacebo in Patients With BCRL
Started2822
Completed107
Not completed1815
Withdrew: Adverse event21
Withdrew: Withdrawal by subject42
Withdrew: Covid-19 lock down10
Withdrew: Study terminated by sponsor1112

Outcome measures

PrimarySafety and Tolerability: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

Evaluate the safety and tolerability of LYT-100 as measured by TEAEs

Time frame:
6 months
Reported as:
Count of participants · Participants
Safety and Tolerability: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsLYT-100 in Patients With BCRLPlacebo in Patients With BCRL
Safety and Tolerability: Number of Participants With Treatment-emergent Adverse Events (TEAEs)2213

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LYT-100 in Patients With BCRL0/28 (0%)0/28 (0%)22/28 (78.6%)
Placebo in Patients With BCRL0/22 (0%)2/22 (9.1%)13/22 (59.1%)
Most frequent serious events
Most frequent serious events
EventLYT-100 in Patients With BCRLPlacebo in Patients With BCRL
PyelonephritisInfections and infestations0/281/22
Radius FractureInjury, poisoning and procedural complications0/281/22
Most frequent other events
Showing 10 of 12
Most frequent other events
EventLYT-100 in Patients With BCRLPlacebo in Patients With BCRL
NauseaGastrointestinal disorders13/282/22
DiarrhoeaGastrointestinal disorders5/282/22
DyspepsiaGastrointestinal disorders4/280/22
COVID-19Infections and infestations4/281/22
HeadacheNervous system disorders4/283/22
FatigueGeneral disorders4/283/22
InsomniaPsychiatric disorders3/280/22
ConstipationGastrointestinal disorders2/282/22
Urinary Tract InfectionInfections and infestations0/282/22
DizzinessNervous system disorders0/282/22

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)LYT-100 in Patients With BCRLPlacebo in Patients With BCRLTotal
<=18 years000
Between 18 and 65 years211839
>=65 years7411
Sex: Female, Male
Sex: Female, Male(Participants)LYT-100 in Patients With BCRLPlacebo in Patients With BCRLTotal
Female282250
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LYT-100 in Patients With BCRLPlacebo in Patients With BCRLTotal
Hispanic or Latino011
Not Hispanic or Latino282048
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)LYT-100 in Patients With BCRLPlacebo in Patients With BCRLTotal
United States9918
Australia191332
08

Study locations

8 sites
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • MACRO Trials
    Los Angeles, California 91105, United States
  • Accel Research Network
    Maitland, Florida 32751, United States
  • Accel Research Network
    Atlanta, Georgia 30342, United States
  • University of the Sunshine Coast
    Sippy Downs, Queensland, Australia
  • Ballarat Health Services
    Ballarat, Victoria, Australia
  • Flinders University
    Adelaide, Australia
  • Macquarie University Health Sciences Centre
    Sydney, Australia
09

References and documents

Publications

  • Chen MC, Korth CC, Harnett MD, Elenko E, Lickliter JD. A Randomized Phase 1 Evaluation of Deupirfenidone, a Novel Deuterium-Containing Drug Candidate for Interstitial Lung Disease and Other Inflammatory and Fibrotic Diseases. Clin Pharmacol Drug Dev. 2022 Feb;11(2):220-234. doi: 10.1002/cpdd.1040. Epub 2021 Nov 15. PubMed 34779583 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Sep 2022, 30 months.

Results were first posted in Apr 2024, 1 year 7 months after primary completion. A results delay was requested in Sep 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2020
First posted
Jan 28, 2020
StartActual
Mar 1, 2020
Primary completionActual
Sep 9, 2022
CompletionActual
Sep 9, 2022
Results delay requested
Sep 7, 2023
Results first posted
Apr 23, 2024
Last update
Apr 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04243837
Lead sponsor
PureTech
Collaborators
Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
Jan 28, 2020
Start date
Mar 1, 2020
Primary completion
Sep 9, 2022
Completion
Sep 9, 2022
Results posted
Apr 23, 2024
Last update
Apr 23, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion